Proposed Data Collection Submitted for Public Comment and Recommendations, 35798-35799 [2021-14437]
Download as PDF
<![CDATA[
35798
Federal Register / Vol. 86, No. 127 / Wednesday, July 7, 2021 / Notices
technologies. Adding these measures to
the NQDW survey instruments will
impose minimal additional burden on
states but will substantially improve the
utility of the NQDW data to identify use
of state quitlines by key tobacco use
populations and through modalities
other than telephone calls. Participation
in the caller intake and follow-up
interviews is voluntary for quitline
callers. The estimated burden is 10
minutes for a complete intake call
conducted with an individual who calls
on their own behalf. The estimated
burden is one minute for a caller who
requests information for someone else,
as these callers complete only a subset
of questions on the intake questionnaire.
As a condition of funding (CDC–RFA–
DP20–2001), the 54 cooperative
agreement awardees are required to
submit NQDW intake data quarterly,
and services survey data semiannually.
CDC recognizes that awardees incur
additional burden for preparing and
transmitting summary files with their
de-identified caller intake and follow-up
data. This burden is acknowledged in
the instructions for transmitting the
electronic data files. There is a net
decrease in burden hours from the
previous NQDW package estimate. This
is primarily due to decreases in the
overall number of telephone calls to the
quitlines, which is estimated to be only
partially offset by the use of other
quitline modalities. The total estimated
annual Burden Hours for the NQDW are
68,088. There is no cost to respondents
other than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
respondent
(in hours)
Total burden
(in hours)
Form name
Quitline participants who contact the quitline for
help for themselves.
NQDW Intake Questionnaire (English-complete).
ASQ Intake Questionnaire (Chinese, Korean,
or Vietnamese-complete).
ASQ Seven-Month Follow-up Questionnaire ....
NQDW Intake Questionnaire (English-subset)
ASQ Intake Questionnaire (Chinese, Korean,
or Vietnamese-subset).
Submission of NQDW Intake Questionnaire
Electronic Data File to CDC.
Submission of NQDW (ASQ) Seven-Month
Follow-up Electronic Data File to CDC.
NQDW Quitline Services Survey ......................
405,053
1
10/60
67,509
1,686
1
10/60
281
236
819
249
1
1
1
7/60
1/60
1/60
28
14
4
54
4
1
216
1
1
1
1
54
2
20/60
36
...........................................................................
........................
........................
........................
68,088
Participants who contact the quitline on behalf
of someone else.
Tobacco Control Manager or their Designee/
quitline Service Provider.
Total ............................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–14441 Filed 7–6–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–21–21FS; Docket No. CDC–2021–
0059]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondent
VerDate Sep<11>2014
17:44 Jul 06, 2021
Jkt 253001
This notice invites comment on a
proposed information collection project
titled The Muscular Dystrophy
Surveillance, Tracking, and Research
Network (MD STARnet) Muscular
Dystrophy Questionnaire:
Understanding the impact of COVID–19,
flu, pain, fatigue, pregnancy and
infertility, on adults with muscular
dystrophy. The purpose of the proposed
study is to describe the epidemiology of
COVID–19 and flu and the experience
with pain, fatigue, pregnancy, and
infertility for adults living with
muscular dystrophy who are identified
through the Muscular Dystrophy
Surveillance Tracking and Research
Network (MD STARnet). Information
will be used to develop interventions
that improve the lives of people with
muscular dystrophy and their families.
DATES: CDC must receive written
comments on or before September 7,
2021.
You may submit comments,
identified by Docket No. CDC–2021–
0059 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
ADDRESSES:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
E:\FR\FM\07JYN1.SGM
07JYN1
35799
Federal Register / Vol. 86, No. 127 / Wednesday, July 7, 2021 / Notices
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
The Muscular Dystrophy
Surveillance, Tracking, and Research
Network (MD STARnet) Muscular
Dystrophy Questionnaire:
years old. MD STARnet aims to improve
understanding of MDs and ultimately
the quality of life of people and their
families living with MD. Individuals
with MDs frequently report pain and
fatigue, but studies have largely been
conducted in clinic-based populations
and included the three most common
MDs. Population-based studies are
needed to describe the frequency and
management of pain and fatigue and
their impact on the lives of individuals
with various types of MD.
The purpose of the proposed study is
to describe the epidemiology of COVID–
19 and flu and the experience with pain,
fatigue, pregnancy, and infertility for
adults living with muscular dystrophy
who are identified through the Muscular
Dystrophy Surveillance Tracking and
Research Network (MD STARnet).
Results generated from the study will
provide a better understanding of (1) the
occurrence, testing, treatment and
severity of COVID–19 in relation to MD;
(2) vaccination status and reasons for
not receiving COVID–19 and flu
vaccinations; (3) the frequency,
intensity, and management of pain and
fatigue; and (4) the effect of having
muscular dystrophy on pregnancy and
fertility on adults living with muscular
dystrophy. Ultimately, this information
can be used by stakeholders to develop
interventions that improve the lives of
people with muscular dystrophy and
their families.
Understanding the impact of COVID–19,
flu, pain, fatigue, pregnancy and
infertility, on adults with muscular
dystrophy—New—National Center on
Birth Defects and Developmental
Disabilities (NCBDDD), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Since its establishment in 2002, the
MD STARnet has been a populationbased surveillance system that aims to
identify and collect clinical data on
individuals with muscular dystrophy
(MD) in select surveillance areas. MD
STARnet identifies and collects data on
cases at sources including healthcare
facilities where patients with MD
receive care, and administrative datasets
such as vital records and hospital
discharge data. While MDs are rare
genetic diseases with an estimated
prevalence of 16.1/100,000, they have a
high impact on affected individuals,
their families, and society. MDs can be
classified into nine major groups:
Duchenne muscular dystrophy (DMD),
Becker muscular dystrophy (BMD),
myotonic dystrophy (DM),
facioscapulohumeral muscular
dystrophy (FSHD), limb-girdle muscular
dystrophy (LGMD), Congenital muscular
dystrophy (CMD), Emery-Dreifuss
muscular dystrophy (EDMD), and distal
muscular dystrophy. A recent MD
STARnet study has estimated the
combined prevalence for DMD and BMD
to be 1.92–2.48/10,000 males age 5–9
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Average
burden per
response
(in hours)
Total burden
hours
Form name
Adult males 18 and over ...................
Adult females 18 and over ................
MD STARnet male questionnaire ....
MD STARnet female questionnaire
1,794
1,574
1
1
15/60
20/60
449
525
Total ...........................................
...........................................................
........................
........................
........................
974
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–14437 Filed 7–6–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
[30Day–21–21BG]
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Type of respondents
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Prevention
Research Centers National Program
Evaluation Reporting System (PERS) to
VerDate Sep<11>2014
17:44 Jul 06, 2021
Jkt 253001
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on December 18, 2020 to obtain
comments from the public and affected
agencies. CDC received one comment
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
E:\FR\FM\07JYN1.SGM
07JYN1
]]>Agencies
[Federal Register Volume 86, Number 127 (Wednesday, July 7, 2021)]
[Notices]
[Pages 35798-35799]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14437]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-21-21FS; Docket No. CDC-2021-0059]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled The Muscular Dystrophy
Surveillance, Tracking, and Research Network (MD STARnet) Muscular
Dystrophy Questionnaire: Understanding the impact of COVID-19, flu,
pain, fatigue, pregnancy and infertility, on adults with muscular
dystrophy. The purpose of the proposed study is to describe the
epidemiology of COVID-19 and flu and the experience with pain, fatigue,
pregnancy, and infertility for adults living with muscular dystrophy
who are identified through the Muscular Dystrophy Surveillance Tracking
and Research Network (MD STARnet). Information will be used to develop
interventions that improve the lives of people with muscular dystrophy
and their families.
DATES: CDC must receive written comments on or before September 7,
2021.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0059 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7118; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
[[Page 35799]]
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
The Muscular Dystrophy Surveillance, Tracking, and Research Network
(MD STARnet) Muscular Dystrophy Questionnaire: Understanding the impact
of COVID-19, flu, pain, fatigue, pregnancy and infertility, on adults
with muscular dystrophy--New--National Center on Birth Defects and
Developmental Disabilities (NCBDDD), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Since its establishment in 2002, the MD STARnet has been a
population-based surveillance system that aims to identify and collect
clinical data on individuals with muscular dystrophy (MD) in select
surveillance areas. MD STARnet identifies and collects data on cases at
sources including healthcare facilities where patients with MD receive
care, and administrative datasets such as vital records and hospital
discharge data. While MDs are rare genetic diseases with an estimated
prevalence of 16.1/100,000, they have a high impact on affected
individuals, their families, and society. MDs can be classified into
nine major groups: Duchenne muscular dystrophy (DMD), Becker muscular
dystrophy (BMD), myotonic dystrophy (DM), facioscapulohumeral muscular
dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), Congenital
muscular dystrophy (CMD), Emery-Dreifuss muscular dystrophy (EDMD), and
distal muscular dystrophy. A recent MD STARnet study has estimated the
combined prevalence for DMD and BMD to be 1.92-2.48/10,000 males age 5-
9 years old. MD STARnet aims to improve understanding of MDs and
ultimately the quality of life of people and their families living with
MD. Individuals with MDs frequently report pain and fatigue, but
studies have largely been conducted in clinic-based populations and
included the three most common MDs. Population-based studies are needed
to describe the frequency and management of pain and fatigue and their
impact on the lives of individuals with various types of MD.
The purpose of the proposed study is to describe the epidemiology
of COVID-19 and flu and the experience with pain, fatigue, pregnancy,
and infertility for adults living with muscular dystrophy who are
identified through the Muscular Dystrophy Surveillance Tracking and
Research Network (MD STARnet).
Results generated from the study will provide a better
understanding of (1) the occurrence, testing, treatment and severity of
COVID-19 in relation to MD; (2) vaccination status and reasons for not
receiving COVID-19 and flu vaccinations; (3) the frequency, intensity,
and management of pain and fatigue; and (4) the effect of having
muscular dystrophy on pregnancy and fertility on adults living with
muscular dystrophy. Ultimately, this information can be used by
stakeholders to develop interventions that improve the lives of people
with muscular dystrophy and their families.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
Adult males 18 and over....... MD STARnet male 1,794 1 15/60 449
questionnaire.
Adult females 18 and over..... MD STARnet 1,574 1 20/60 525
female
questionnaire.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 974
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-14437 Filed 7-6-21; 8:45 am]
BILLING CODE 4163-18-P
